Biocartis, Hospital del Mar deal

Hospital del Mar granted Biocartis a license to the S492R mutation on the EGFR gene for developing a colon cancer test. The partners said the mutation can help identify patients who are resistant to cetuximab while remaining sensitive to panitumumab. The partners declined to disclose details. ...